Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal phase III trial of MAT 9001 for the treatment of severe hypertriglyceridaemia and mixed dyslipidaemia

Next Previous
Trial Profile

Pivotal phase III trial of MAT 9001 for the treatment of severe hypertriglyceridaemia and mixed dyslipidaemia

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 23 Dec 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MAT 9001 (Primary)
  • Indications Dyslipidaemias; Hypertriglyceridaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Matinas BioPharma

    • Most Recent Events

    • 29 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top